Vuno Inc.
Financials
Valuation Metrics
Vuno Inc.'s Market Cap is ₩1133B. At end of 2025 it was ₩3129B. Ranked #1147 of 2,436 in KR market (top 47%), #596 of 1,649 on KOSDAQ (top 36%), #40 of 96 in Health Care Equipment & Services (top 42%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 113.27B KRW | KR#1,147/2,436 Sec#40/96 |
| Revenue | 33.36B KRW | KR#1,987/2,436 Sec#61/96 |
| Net Income | -6.48B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 54.73B KRW | KR#2,147/2,436 Sec#72/96 |
| Net Assets | 41.12B KRW | KR#2,007/2,436 Sec#71/96 |
| Employees | 160 | KR#1,262/2,436 Sec#41/96 |
| Value | ||
| P/B | 2.75x | KR#2,081/2,436 Sec#76/96 |
| P/S | 3.40x | KR#2,043/2,436 Sec#66/96 |
| FCF Yield | -4.72% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -15.76% | KR#2,009/2,436 Sec#69/96 |
| ROA | -11.84% | KR#2,117/2,436 Sec#72/96 |
| Op. Margin | -16.83% | KR#2,085/2,436 Sec#69/96 |
| Revenue Growth | -19.74% | KR#2,060/2,436 Sec#80/96 |
| Financial Health | ||
| Debt Ratio | 133.11% | KR#908/2,436 Sec#40/96 |
| Total Debt | 6.26B KRW | KR#1,737/2,436 Sec#61/96 |
| FCF | -5.35B KRW | KR#1,516/2,436 Sec#51/96 |
| Cash | 5.08B KRW | KR#1,978/2,436 Sec#70/96 |
| Current Ratio | 3.55x | KR#506/2,436 Sec#31/96 |
| Performance | ||
| 1Y Return | -57.82% | KR#2,209/2,436 Sec#82/96 |
| 1M Return | 3.59% | KR#568/2,436 Sec#29/96 |
| From 52W High | -71.46% | KR#2,180/2,436 Sec#81/96 |
| 1Y MDD | -76.05% | KR#2,185/2,436 Sec#85/96 |
| Trading | ||
| Volume | 46,024 shares | KR#1,378/2,436 Sec#60/96 |
| Foreign Own. | 3.21% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -463 KRW | KR—/2,436 Sec—/96 |
| BPS | 2,937 KRW | KR#1,827/2,436 Sec#54/96 |
Company Info
Vuno, an artificial intelligence medical enterprise founded in 2014, initiated its global business after launching South Korea's first AI medical device in 2018 and listing on KOSDAQ in 2021. The company uses deep learning to analyze medical data, offering diagnostic and predictive products for cardiac arrest risk, lesion detection, X-ray findings, and arrhythmia analysis. By developing its own AI engine, Vuno has reduced dependence on IT companies and is accelerating global market expansion, including securing FDA breakthrough device designation. It is headquartered in Seocho-gu, Seoul.